ClinicalTrials.gg
RecruitingNCT07012044Updated Oct 23, 2026

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

A Phase 1 interventional study of Biospecimen Collection and Bone Marrow Aspiration in Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia, sponsored by National Cancer Institute (NCI). Recruiting at 15 sites in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 23, 2026Site recruiting status changed3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.

Planned enrollment
46th of 120
47 · median 32
Started
2026
with 7 others
Phase 1
37 of 121
6 open now
Primary completion
2027-03
later than 14 of 32 live
Registered
112th of 121
by date
Lead sponsor
13 of 121
National Cancer Institute (NCI)

Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 46th largest by planned enrollment of the 120 interventional ones that give a count, is one of 8 that started in 2026, is one of 37 in phase 1, reaches primary completion later than 14 of the 32 other live ones, and was the 112th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing decitabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) who have undergone allogenic hematopoietic stem cell transplantation. ASTX727 is a combination of cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine when taken by mouth, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Filgrastim works in synergy with decitabine and enhances its activity. Giving ATSX727 and filgrastim may be safe and tolerable in treating children with high risk, recurrent or refractory acute myeloid leukemia who have undergone allogenic hematopoietic stem cell transplantation.

Read the detailed description

PRIMARY OBJECTIVES:

I. To estimate the maximum tolerated dose and/or recommended phase 2 dose (RP2D) of decitabine and cedazuridine (ASTX727) administered together with filgrastim (rh-granulocyte colony stimulating factor [GCSF]) post-hematopoietic stem cell transplant (HCT) to children with high-risk acute myeloid leukemia (AML).

II. To define and describe the toxicities of ASTX727 administered together with filgrastim (rh-GCSF) post-HCT in children with high-risk AML.

III. To characterize the pharmacokinetic profile of ASTX727 administered together with filgrastim (rh-GCSF) post-HCT in children with high-risk AML.

SECONDARY OBJECTIVES:

I. To determine the incidence and severity of graft versus host disease and graft rejection in children with high-risk AML who received post-HCT therapy with ASTX727 and filgrastim (rh-GCSF).

II. To preliminarily describe the 1-year event free survival (EFS) of patients with AML who received post-HCT therapy with ASTX727 and filgrastim (rh-GCSF), within the confines of a phase 1 study.

EXPLORATORY OBJECTIVE:

I. To characterize the pharmacodynamic profile of ASTX727 through deoxyribonucleic acid (DNA) methylation assay and, in turn, the potential impact of hypomethylation on donor immune cells and the graft versus leukemia effect.

OUTLINE: This is a dose-escalation study of decitabine in combination with cedazuridine and filgrastim.

Patients receive filgrastim subcutaneously (SC) or intravenously (IV) once daily (QD) on days 1-6 and ASTX727 orally (PO) QD on days 2-6. Patients may receive decitabine (with no cedazuridine) PO QD on days 2-6 to achieve the appropriate dose. Cycles repeat every 28 days up to12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and biopsy and blood sample collection throughout the study and may undergo lumbar puncture and diagnostic imaging throughout the study.

After completion of study treatment, patients are followed up at 1 year post transplant and/or at relapse.

03

Conditions studied

  • Acute Myeloid Leukemia Post Cytotoxic Therapy
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • STEP 0: Patient must be ≤ 21 years of age

    • PLEASE NOTE: Eligibility criteria to enroll onto Step 1 for the treatment trial is ≤ 21 years of age at the time of Step 1 enrollment. Please plan accordingly to ensure that patients who are screened with Step 0 will be at an eligible age at the time of enrollment onto Step 1. Patients who are 21 at the time of screening who turn 22 at the time of enrollment onto Step 1 will not be eligible to enroll onto the study
  • STEP 0: Patients with newly diagnosed high risk* de novo AML, newly diagnosed therapy-related AML, , or refractory AML. in complete remission at the time of transplant. Patients with a history of isolated or combined central nervous system (CNS) or extramedullary disease are eligible if they have no evidence of active CNS or extramedullary disease at the time of trial enrollment (Step 0) and treatment enrollment (Step 1). Eligible patients with histories of isolated or combined CNS or extramedullary disease at time of relapse are required to be in complete remission at time of transplant to be eligible for this study

    • Based on risk criteria adopted by the AAML1831 study
  • STEP 0: Patient must plan to have bone marrow sample submitted to Hematologics within 14 days prior to the start of conditioning regimen for HCT.

    • Note: In order to be eligible to enroll onto Step 1 to receive treatment on this study, pre-HCT disease status must be assessed prior to receiving HCT. AML must be in complete remission (Children's Oncology Group [COG]-complete remission [CR], COG-complete remission with partial recovery of platelelt count [CRp], COG-complete remission with incomplete blood count recovery [Cri], with or without detectable minimal residual disease [MRD]); bone marrow CR must be assessed by central flow cytometry performed at Hematologics prior to the start of the conditioning regimen
  • STEP 0: (HIV)-infected patients are eligible for this trial if the following criteria are met:

    • No history of HIV complications with the exception of \< 200cells/mm\^3
    • No antiretroviral therapy with overlapping toxicity such as myelosuppression
    • CD4 count > 500 cells/mm\^3 prior to the diagnosis of newly diagnosed, relapsed, refractory AML.
    • HIV viral loads below the limit of detection within 6 months, as long as the patient is NOT receiving anti-retroviral agents that may interact with ASTX727.
    • No history of highly active antiretroviral therapy (HAART)-resistant HIV
  • STEP 0: Patients must be receiving an allogeneic (related, unrelated, and mismatched related, including haploidentical) marrow, peripheral blood, or cord blood transplant for the first time
  • STEP 0: HCT conditioning regimen must be planned to begin within 14 days after bone marrow assessment to determine disease status
  • STEP 0: Conditioning regimen must be myeloablative and include high dose busulfan, or treosulfan, or total body irradiation
  • STEP 0: Patients must not have received prior exposure to ASTX727. Note that patients may have had prior exposure to decitabine
  • STEP 1: Patient must be ≤ 21 years of age at the time of study enrollment to step 0 and step 1
  • STEP 1: Patients must have a body surface area ≥ 1m\^2 at enrollment to step 1
  • STEP 1 (PRE-HCT): AML must be in complete remission (COG-CR, COG-CRp, COG-Cri), with or without detectable MRD; bone marrow CR must be assessed by central flow cytometry performed at Hematologics. Disease assessment must be performed within 14 days prior to the start of HCT conditioning regimen

    • Patients with CNS or extramedullary disease within 14 days prior to the start of the HCT condition regimen are not eligible
  • STEP 1 (POST-HCT): AML must be in complete remission (COG-CR, COG-CRp, COG-CRi). Bone marrow evaluation must show CR with no detectable minimal residual disease (MRD negative by central flow cytometry at Hematologics)

    • Note: Disease assessment is required to be performed within 14 days prior to enrollment onto Step 1
    • Patients with CNS or extramedullary disease post-HCT are not eligible
  • STEP 1: Patients must have a performance status corresponding to (ECOG) scores of 0, 1 or 2. Use for patients > 16 years of age and Lansky for patients ≤ 16 years of age. Patients must have Karnofsky performance score ≥ 50 or Lansky play-performance scale score ≥ 50
  • STEP 1: Patients must have fully recovered from the acute toxicities related to the conditioning regimen and the transplant. If, after 42-100 days post-transplant, the eligibility criteria are met, the patient is considered to have recovered adequately
  • STEP 1: count ≥ 50,000 µL (without requirement for platelet transfusion within the last 7 days)
  • STEP 1: ≥ 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)
  • STEP 1: ≥ 1,000 µL with no myeloid growth factor support within the last 3 days
  • Estimated (GFR) (eGFR) ≥ 60 mL/min/1.73 m\^2 "Bedside" Schwartz formula (2009) OR

    • OR- A 24 hour urine ≥ 60 mL/min/1.73 m\^2
    • A GFR ≥ 60 mL/min/1.73 m\^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
    • Note: Estimated GFR (eGFR) from cystatin C or other estimates not listed above are not acceptable for determining eligibility
  • STEP 1: (total or sum of conjugated + unconjugated) ≤ 1.5 x (ULN) for age
  • STEP 1: (ALT) ≤ 3 x ULN
  • STEP 1: Aspartate aminotransferase (AST) ≤ 3 x ULN
  • STEP 1: Albumin ≥ 2 g/dL

Exclusion criteria

Exclusion Criteria:

  • STEP 0: Patients with known inherited marrow failure syndromes, including, but not limited to Fanconi Anemia, Dyskeratosis congenita, and Shwachman-Diamond syndrome
  • STEP 0: Known or suspected to filgrastim, decitabine or cedazuridine (ASTX727)
  • STEP 0: Patients who have received a prior solid organ transplantation are not eligible
  • STEP 1: ASTX727 can cause fetal harm when administered to pregnant women. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of may not participate unless they have agreed to use two effective methods of , including a medically accepted barrier or contraceptive method (eg, male or female condom) for the duration of the study. Abstinence is an acceptable method of birth control. Women of must use highly effective contraception during treatment with ASTX727 and for at least 6 months after the last dose. Men with female partners of childbearing potential should be advised to practice highly effective contraceptive measures of birth control and not to father a child while receiving treatment with decitabine and for 3 months after the last dose. Breastfeeding is not allowed during the study and for at least 2 weeks after the last dose of study drug
  • STEP 1: Patients who are currently receiving another drug are not eligible
  • STEP 1: Patients who are currently receiving other anti-cancer agents are not eligible. Patients receiving intrathecal chemotherapy in the prior 14 days are eligible
  • STEP 1: Patients receiving or for whom there is a plan to administer anticancer non-protocol therapy, radiation therapy or immunotherapy during the study period are not eligible (note that prophylactic use of chemotherapeutic agents for [GVHD] is allowed, e.g. methotrexate for GVHD prophylaxis). Intrathecal cytarabine administered at the discretion of the treating physician throughout maintenance therapy is allowed
  • STEP 1: Drugs known to be metabolized by cytidine deaminase (CDA) should not be given (such drugs include cytarabine, gemcitabine, azacitidine, vidarabine, zalcitabine, zidovudine, telbivudine, didanosine, stavudine, lamivudine, abacavir, emtricitabine, entecavir, trifluridine, tenofovir and adefovir) on days when ASTX727 is administered and for 24 hours thereafter
  • STEP 1: Patients is not able to swallow intact tablets. Nasogastric or G tube administration is not allowed
  • STEP 1: Patient is not able to start ASTX727 and filgrastim (rh-GCSF) between day 42 and day 100 following completion of allo-HCT. If, after enrollment, protocol therapy is started more than 100 days following allo-HCT, the patient will be removed from protocol therapy
  • STEP 1: Patients with graft loss are not eligible
  • STEP 1: Patients with or dependent acute GVHD are not eligible. Patients must be on \< 1 mg/kg/day of methylprednisolone (or equivalent prednisone/prednisolone dose) that is being tapered. Patients must not be on any systemic therapies. Continued GVHD prophylaxis with calcineurin inhibitors, sirolimus, abatacept or mycophenolate mofetil is acceptable
  • STEP 1: Patients who have an uncontrolled viral, bacterial, fungal, or protozoal infection are not eligible
  • STEP 1: Patients with active transplant associated thrombotic microangiopathy with ongoing hemolysis and need treatment (e.g. eculizumab) are not eligible
  • STEP 1: Patients with sinusoidal obstruction syndrome with ongoing need for treatment (e.g. defibrotide, diuresis, supplemental oxygen) are not eligible
  • STEP 1: Idiopathic pneumonitis syndrome or other non-infectious lung injury requiring ongoing treatment (corticosteroids, tumor necrosis factor [TNF] inhibitors, or other biologics) or supplemental oxygen are not eligible
  • STEP 1: Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (estimated)

Study arms

  • Experimental
    Treatment (ASTX727, diecitabine, filgrastim)

    Patients receive filgrastim SC or IV QD on days 1-6 and ASTX727 orally (PO) QD on days 2-6. Patients may receive decitabine (with no cedazuridine) PO QD on days 2-6 to achieve the appropriate dose. Cycles repeat every 28 days up to12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and biopsy and blood sample collection throughout the study and may undergo lumbar puncture and diagnostic imaging throughout the study.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Decitabine · Drug: Decitabine and Cedazuridine · Biological: Filgrastim · Procedure: Imaging Procedure · Procedure: Lumbar Puncture

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • Given PO

    Also known as: 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine

  • DrugDecitabine and Cedazuridine

    Given PO

    Also known as: ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi

  • BiologicalFilgrastim

    Given SC or IV

    Also known as: Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio

  • ProcedureImaging Procedure

    Undergo diagnostic imaging

    Also known as: Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), Imaging Procedures, Imaging Technique, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging

  • ProcedureLumbar Puncture

    Undergo lumbar puncture

    Also known as: LP, Spinal Tap

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose of ASTX727

    Defined as maximum dose at which fewer than one-third of patients experience dose limiting toxicity.

    Time frame: Up to completion of cycle 2 (cycle length=28 days)

  2. Incidence of adverse events of ASTX727

    Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 2 years

  3. Area under the concentration by time curve of ASTX727

    Median area under the concentration over time curve assessed at 1 and 3 hours post dose in cycle 1 stratified by dose level.

    Time frame: Up to 28 days

  4. Half life of ASTX727

    Median half-life of ASTX727 stratified by dose level assessed at 1 and 3 hours post dose in cycle 1 stratified by dose level.

    Time frame: Up to 28 days

  5. Clearance of ASTX727

    Median clearance of ASTX727 assessed at 1 and 3 hours post dose in cycle 1 stratified by dose level.

    Time frame: Up to 28 days

Secondary outcomes

  1. Incidence of graft versus host disease of ASTX727

    Frequency of graft versus host disease stratified by dose level.

    Time frame: Up to 2 years

  2. Severity of graft versus host disease of ASTX727

    Frequency of graft versus host disease severity score stratified by dose level.

    Time frame: Up to 2 years

  3. Incidence of graft rejection of ASTX727

    Frequency of graft rejection stratified by dose level.

    Time frame: Up to 2 years

  4. Severity of graft rejection of ASTX727

    Frequency of graft rejection severity score by dose level.

    Time frame: Up to 2 years

  5. Event free survival of ASTX727

    Median time to event stratified by dose level.

    Time frame: At 1 year

Other outcomes

  1. Pharmacodynamic profile of ASTX727

    Assessed through deoxyribonucleic acid methylation assay.

    Time frame: At cycle 1 day 1 and cycle 1 day 8

07

Study locations

14 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2027, 9 months after the start.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's planned 9 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2025
First posted
Jun 10, 2025
StartActual
Jun 9, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. Riley Hospital for Children is now Not yet recruiting
Show 3 added (3 United States)
  • Seattle Children's Hospital · Seattle, United States
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center · Houston, United States
  • UCSF Medical Center-Mission Bay · San Francisco, United States
across 4 updates, Oct 5, 2026 – Oct 23, 2026
Show all 4 updates
  1. Oct 23, 2026
    Riley Hospital for Children is now Not yet recruiting
  2. Oct 22, 2026
    1 site added
    Show site
    • UCSF Medical Center-Mission Bay · San Francisco, United States
  3. Oct 19, 2026
    1 site added
    Show site
    • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center · Houston, United States
  4. Oct 5, 2026
    1 site added
    Show site
    • Seattle Children's Hospital · Seattle, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07012044
Responsible party
Sponsor
First posted
Jun 10, 2025
Start date
Jun 9, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Maria Luisa Sulis
principal investigator · Pediatric Early Phase Clinical Trial Network

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Decitabine · Filgrastim

Start the discussion